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Abstract 
Microsatellite repeat expansion disease loci can exhibit pleiotropic clinical and biological 
effects depending on repeat length. Large expansions in C9orf72 (100s-1000s of units) are the 
most common genetic cause of amyotrophic lateral sclerosis (ALS) and frontotemporal 
degeneration (FTD). However, whether intermediate expansions also contribute to 
neurodegenerative disease is not well understood. Several studies have identified intermediate 
repeats in Parkinson’s disease patients, but the association was not found in autopsy confirmed 
cases. We hypothesized that intermediate C9orf72 repeats are a genetic risk factor for 
corticobasal degeneration (CBD), a neurodegenerative disease that can be clinically similar to 
Parkinson’s but has distinct tau protein pathology.  Indeed, intermediate C9orf72 repeats were 
significantly enriched in autopsy-proven CBD (n=354 cases, odds ratio=3.59, p-value=0.00024).  
While large C9orf72 repeat expansions are known to decrease C9orf72 expression, intermediate 
C9orf72 repeats result in increased C9orf72 expression in human brain tissue and CRISPR/cas9 
76 
3 
knockin iPSC derived neural progenitor cells. In contrast to cases of FTD/ALS with large 77 
C9orf72 expansions, CBD with intermediate C9orf72 repeats was not associated with pathologic 78 
RNA foci or dipeptide repeat protein aggregates.  Knock-in cells with intermediate repeats 79 
exhibit numerous changes in gene expression pathways relating to vesicle trafficking and 80 
autophagy. Additionally, overexpression of C9orf72 without the repeat expansion leads to 81 
defects in autophagy under nutrient starvation conditions. These results raise the possibility that 82 
therapeutic strategies to reduce C9orf72 expression may be beneficial for the treatment of CBD. 83 
84 
85 
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Introduction 86 
87 
Large hexanucleotide repeat expansions (G4C2) in C9orf72 are the most common genetic 88 
cause of the neurodegenerative diseases amyotrophic lateral sclerosis (ALS) and frontotemporal 89 
degeneration (FTD)[19, 49, 60]. ALS/FTD is characterized neuropathologically by the presence 90 
of TDP-43 inclusions which are tightly linked to neurodegeneration[35].  While the 91 
pathophysiologic mechanisms that lead to TDP-43 aggregation and neurodegeneration in the 92 
setting of large C9orf72 repeat expansions are still unclear, both a loss of normal C9orf72 93 
function and a toxic gain of function attributed to repetitive RNA and protein aggregates have 94 
been proposed[19, 36, 60, 63, 67]. At the protein level, C9orf72 regulates several vesicle 95 
trafficking pathways [4, 26, 79] and is necessary for proper myeloid cell function in mice, but 96 
knockout of the protein does not cause neurodegeneration[12, 58]. On the other hand, the 97 
presence of the repeat expansion is sufficient to induce neurodegeneration in several mouse 98 
models[15, 42]. There is also uncertainty in the repeat size threshold necessary to cause disease. 99 
Repeat expansions that cause ALS/FTD are typically hundreds to thousands of units long and 100 
can differ substantially between tissues[10, 70], making it difficult to accurately determine the 101 
pathogenic repeat size threshold. There have been reports of pathogenic repeats as small as 55-102 
100 units in patient blood[23, 28].  In contrast, non-diseased individuals typically harbor repeats 103 
of 2-8 units[20]. Several studies have explored whether intermediate expansions (e.g. those 104 
larger than controls but not large enough to cause ALS/FTD) are associated with risk for other 105 
neurodegenerative diseases, and these have often yielded conflicting results[1, 20, 30, 32, 37, 56, 106 
80, 84, 86].  For instance, a significant association between intermediate expansion carriers and 107 
Parkinson’s Disease (PD) was reported in clinically diagnosed PD[56] and confirmed in a large 108 
meta-analysis[73], but these associations were not found in an autopsy confirmed PD cohort[57].  109 
5 
Other studies with very small numbers of cases have also suggested that intermediate C9orf72 110 
repeats are associated with atypical Parkinsonian syndromes[13, 64].  Thus, there is some 111 
evidence that intermediate expansions in C9orf72 may confer risk for neurodegenerative diseases 112 
other than ALS/FTD, but more exploration is needed to better understand the molecular 113 
pathways and exact neurodegenerative diseases that are affected. 114 
Here, we sought to determine whether intermediate expansions in C9orf72 are a risk 115 
factor for corticobasal degeneration (CBD), a rare neurodegenerative disease that shares some 116 
similar clinical features with PD such as limb rigidity, bradykinesia, tremor and apraxia[5]. 117 
Patients that present with these neurologic features are often diagnosed with corticobasal 118 
syndrome (CBS) because these symptoms can also be caused by several other neurodegenerative 119 
diseases; definitive diagnosis of CBD requires neuropathology autopsy examination[33].  CBD is 120 
characterized by hyper-phosphorylated tau aggregates in neurons and astrocytes that are 121 
morphologically distinct from those found in Alzheimer’s disease and other tauopathies[21]. 122 
Only ~25-50% of patients diagnosed with CBS are confirmed as CBD at autopsy[11, 39, 40],  123 
making clinically defined cohorts difficult to use for genetic studies of CBD due to underlying 124 
neuropathological heterogeneity.  In this study, we determine whether C9orf72 intermediate 125 
expansions may be a risk factor for CBD by measuring repeat size in the largest cohort of 126 
autopsy confirmed cases ever tested. In addition, we use post mortem CBD brain tissue to 127 
confirm the genetic findings, use CRISPR/cas9 to modify the repeat number in human iPS cells 128 
at the endogenous locus, and determine the effects of C9orf72 expression on autophagy. In doing 129 
so, we identify a novel mechanism for how intermediate repeat expansions may affect CBD 130 
pathogenesis that is distinct from large expansions that cause ALS/FTD. 131 
132 
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Materials and Methods 133 
Case Samples 134 
Genomic DNA for repeat expansion size screening was obtained from 354 autopsy 135 
confirmed CBD cases from 17 institutions, including members of the PSP Genetics Consortium. 136 
The PSP Genetics Consortium is a multinational group studying the genetics of PSP and related 137 
tauopathies including CBD.  Institutions contributing the vast majority of cases included Mayo 138 
Clinc, University College London and the University of Pennsylvania. CBD patient cerebellum 139 
tissue for RNA expression studies was obtained from the Center for Neurodegenerative Disease 140 
Research brain bank at the University of Pennsylvania and from the Mayo Clinic brain bank. 141 
Brain autopsy material is not considered human subjects research.  However, legal consent for 142 
autopsy was obtained in all instances. As a control cohort, we utilized a previously published 143 
global cohort of healthy controls for which C9orf72 repeat sizing was available[73]. 144 
145 
Assessment of Repeat Expansion Size and SNP Genotyping 146 
The CBD cohort was screened for intermediate C9orf72 repeat expansions using 147 
fluorescent labeled touchdown PCR followed by fragment-length analysis on an ABI 3130xl 148 
Genetic Analyzer (Applied Biosystems, Foster City, CA). PCR used 50ng genomic DNA in a 149 
final volume of 20ul containing 0.5U of Amplitaq Gold (Applied Biosystems) and a final 150 
concentration of 1x Amplitaq Buffer I, 5uM reverse primer, 5uM 6FAM-fluorescent labeled 151 
forward primer, 1M Betaine, 5% DMSO, 0.25mM 7-deaza-dGTP, and 0.25mM of each dNTP. 152 
For detection of full expansions using repeat-primed PCR, the Roche FastStart (Roche, Basel, 153 
Switzerland) polymerase system was used to amplify 1ug of genomic DNA in a reaction with 0.9 154 
mM MgCl2, 200nM dNTP mix, 180nM 7-deaza-dGTP, 1.4uM flanking primers, 0.175uM  repeat 155 
7 
primer, 7% DMSO, .93M Betaine and 0.125 U polymerase. For both intermediate and full 156 
expansion detection, a touchdown PCR cycling program was used where the annealing 157 
temperature was gradually lowered from 70°C to 56°C in 2°C increments with a 3-minute 158 
elongation time at 72°C for each cycle. SNP genotyping was carried out using Taqman probes as 159 
previously described[19].  All primer sequences are listed in Supplemental  Table 1. 160 
161 
Detection of RNA foci  162 
RNA foci detection was performed on paraffin embedded cerebellum sections as follows: 163 
Slides were deparaffinized with Xylene, followed by Xylene/Ethanol (1:1) and then rehydrated 164 
with an ethanol series (100%, 90%, 80%,70% for 3 mins each). Slides were incubated for 5 165 
minutes in water, then digested with proteinase K (20ug/mL) for 10 minutes at 37 degrees in a 166 
buffer containing 10mM Tris-HCL pH 8 and 0.5% SDS in DEPC-treated water. Slides were then 167 
washed twice with water then dehydrated with increasing ethanol series and allowed to air dry. 168 
Slides were then prehybridized for 1 hour at 66 degrees in hybridization buffer containing 50% 169 
Foramide, 2X SSC, 50mM NaHPO4 , and 10% Dextran sulfate in DEPC-treated water. Slides 170 
were hybridized with 40nM probe (LNA 5TYE563C4G2; Exiqon (Denmark) # 300500, batch # 171 
621440) at 66 degrees overnight. Slides were then washed once with 2X SSC + 0.1% Tween for 172 
5 mins at room temperature, then 3 times with 0.1X SSC for 10 minutes at 65 degrees. Slides 173 
were then rinsed with water, stained with DAPI and mounted with coverslips using Prolong glass 174 
antifade mountant (Invitrogen, Carlsbad, CA).  Cases for RNA foci detection included 12 non-175 
expanded CBD, 9 intermediate CBD, 4 non-expanded control cases (negative control) and 5 full 176 
expansion FTD/ALS cases (positive control).  177 
178 
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Detection of Dipeptide Repeat proteins and Measurement of DNA methylation 179 
Paraffin embedded cerebellum sections were deparaffinized and stained with antibodies 180 
against p62, GA (1:7500), GP (1:7500) or GR (1:100) as previously described[48]. 116 non-181 
expanded CBD, 9 intermediate CBD, 4 non-expanded control cases (negative control) and 5 full 182 
expansion FTD/ALS cases (positive control) were stained. For measurement of DNA 183 
methylation in CBD patient genomic DNA, 100ng DNA was digested using the restriction 184 
enzymes HhaI and HaeIII (New England Biolabs, Ipswich, MA) followed by qPCR as 185 
previously described[41]. 186 
187 
RNA Expression Analysis from Postmortem Brain and repeat edited NPCs 188 
RNA was extracted from approximately 100mg of cerebellum tissue using Trizol reagent 189 
(Life Technologies, Carlsbad, CA). RNA integrity was tested on an Agilent 2100 bioanalyzer 190 
using the RNA Nanochip 6000 kit (Agilent, Santa Clara, CA). Only RNA samples with RIN 191 
values > 6 were included in this study. For repeat edited NPCs, cells were pelleted at day 12 post 192 
induction and RNA was extracted using the RNeasy Kit (Qiagen). cDNA was prepared using 193 
random hexamers and Superscript III (Invitrogen) according to manufacturer’s protocol. RT-194 
qPCR was performed using SYBR Green reagents (Roche) on a StepOne Plus Real-Time PCR 195 
Machine (Life Technologies). RNA levels were normalized to the geometric mean of two 196 
housekeeping genes (ACTB, GPS1) using the ∆∆Ct method. All primer sequences are listed in 197 
Supplemental  Table 1. 198 
199 
CRISPR Editing of Repeat Size 200 
9 
CRISPR gRNAs were designed using the MIT CRISPR design tool 201 
(http://crispr.mit.edu/) and cloned into the Cas9-GFP PX458 vector (Addgene, Cambridge, MA) 202 
as previously described[59]. Repair templates were generated via PCR cloning using genomic 203 
DNA from intermediate repeat carriers. PCR was carried out using the FastStart Polymerase 204 
(Roche) with additives for GC rich templates (360nM 7-deaza-dGTP, 7% DMSO, 930mM 205 
Betaine). PCR products containing 2 or 28 repeats were cloned into PGEM Easy-T vector 206 
(Promega, Madison, WI) and verified by sequencing. A 2 bp substitution was made at the PAM 207 
site in the repair template using QuickChange site directed mutagenesis (Aligent) in order to 208 
prevent Cas9 cutting of the repair template and to incorporate a restriction enzyme site (See 209 
Supplemental  Figure 3). PX458 and repair template vectors were co-transfected into WT 210 
iPSCs[46] using Viafect reagent (Promega). On day 2 post transfection, GFP+ cells were sorted 211 
via FACS (BD FACS Aria II) to 96 well plates for clonal isolation. DNA was extracted from 24 212 
well plates of confluent clones using 0.2% SDS lysis buffer followed by phenol-chloroform 213 
extraction. DNA from clones was PCR amplified and screened for homology directed repair by 214 
restriction enzyme digest. Repeat size was measured as outlined above on positive clones, and all 215 
CRISPR edited cell lines were Sanger sequenced via PCR cloning (10 clones/cell line).  216 
217 
Differentiation of iPSCs to Neural Progenitor Cells 218 
IPSCs were differentiated via dual SMAD inhibition as previously described[66]. Single 219 
cells were plated at high density (2x105/cm2) in mTeSR1 (StemCell Technologies, Vancouver, 220 
Canada) + 10uM ROCK inhibitor Y27632 (ATCC) on Matrigel (Corning, Corning, NY) coated 221 
6 well plates. The following day, media was changed to neural induction media (see Shi et 222 
al.[66] for complete formulation) containing 10uM SB431542 (Tocris, Bristol, United Kingdom) 223 
10 
and 1uM dorsomorphin (Sigma, St. Louis, MO). Neural induction media was changed each day. 224 
At day 6, cells were split 1:2 into neural induction media + ROCK inhibitor and media changes 225 
were continued until day 12. Day 12 NPCs were characterized for expression of NPC markers by 226 
immunofluorescence and RT-qPCR.  For western blot analysis, NPCs were passaged again at 227 
day 12 and collected at day 16 post induction.  228 
229 
Western Blots and Antibodies  230 
For detection of C9orf72, day 16 NPCs were pelleted, lysed (50mM Tris-HCl, 750mM 231 
NaCl, 5mM EDTA, 2% SDS) and sonicated using a probe sonicator (Sonics Vibra-cell), then 232 
spun at 21,000 g for 30 mins. BCA analysis (Pierce, Thermo Fisher) was performed on cleared 233 
lysate to quantify protein expression. 50ug of protein was run on an 8% Tris-Glycine gel, 234 
transferred using the Transblot Turbo system (Biorad, Hercules, CA) to a nitrocellulose 235 
membrane and blocked for 1 hour at room temperature with Odyssey Licor Blocking buffer 236 
(Licor, Lincoln, NE). Membranes were blotted with the following antibodies overnight at 4 237 
degrees: anti-C9orf72 1:1000 (Millipore, Burlington, MA, ABN1645), anti-GAPDH  1:1000 238 
(Cell signaling Technology, Danvers, MA  2118S). IR dye secondary antibodies (Licor) were 239 
used to detect protein on a Licor Odyssey. Protein was quantified using Image Studio software 240 
(Licor). 241 
For C9orf72 expression and autophagy experiments, cell  lysates  were  prepared  in  ice-242 
cold  radio  immunoprecipitation  assay  (RIPA)  buffer containing  150  mM  NaCl,  1%  243 
TritonX-100,  0.5%  sodium  deoxycholate,  0.1% SDS  and  50 mM  Tris  (pH8.0)  244 
supplemented  with  protease  and  phosphatase inhibitors  (PhosphoSTOP, Roche).  Cells were  245 
lysed  for  20  min  and  centrifuged  for  10  min  at  13,500 rpm.  Protein concentration of the  246 
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soluble  fractions  were  determined  using  BCA  reagent  (Thermo  Fisher Scientific). 20-70ug  247 
of total protein was  resolved  using  10%  or  12%  denaturing polyacrylamide gel 248 
electrophoresis and transferred to PVDF membrane (Immobilon-P, PVDF). Proteins on PVDF 249 
membranes were blocked using 5% low-fat milk in TBST containing 0.1% Tween-20 and 250 
incubated with primary antibody in SuperBlock (TBS, Thermo Fisher Scientific) overnight at 251 
4°C. The primary antibodies used were: LC3 (ProteinTech, 14600-1-AP, 1:1000), and GAPDH 252 
(ProteinTech, 60004-1-Ig, 1:5000). The membranes were washed in TBST. Anti-rabbit  or  anti-253 
mouse  horse-radish  peroxidase  (HRP)  conjugated  secondary  antibodies (1:3000, Thermo 254 
Fisher Scientific) in 5% milk in TBST was incubated with the membranes for 1  h  at room  255 
temperature.  The  membranes  were  incubated  with  WestPico  or  WestFemto 256 
chemiluminescent substrate (Thermo Fisher Scientific) and exposed to Amersham Hyperfilm 257 
ECL films (GE Healthcare Life Sciences). The films were developed using Konica Minolta film 258 
developer. Protein band intensity was quantified using LI-COR Image Studio Lite. 259 
260 
RNA sequencing in knockin intermediate repeat cells 261 
50 base pair paired end RNA sequencing was carried out on day 12 post induction 262 
isogenic NPC lines (See Supplemental  Table 2) with 3 biological replicates per group and 2 263 
technical replicates per cell line. Libraries were prepared using the TrueSeq Stranded mRNA and 264 
Ribo-zero rRNA removal kits (illumina, San Diego, CA). Sequencing was carried out on a Hiseq 265 
2500 (illumina) and at least 100 million reads were generated per biological replicate. Adapter 266 
sequences were removed using Cutadapt[50]. Reads were aligned to the genome (GRCh38) 267 
using STAR (v2.6) [22] with the default mapping parameters and the read counts per gene were 268 
counted using the quantMode function and genecode v29 annotation. Differentially expressed 269 
12 
genes between the short repeat group and intermediate repeat group were called using the 270 
DEseq2 program (v1.22)[45] with default parameters. Over enrichment analysis of biological 271 
pathways was carried out using WebGestalt (2019) on genes that were either upregulated or 272 
downregulated (adjusted p-value < 0.05) in the intermediate repeat group. For comparison of 273 
genes dysregulated in full expansions, differentially expressed gene lists  (adjusted p > 0.05 and 274 
>2 fold change) from two studies[24, 63] that compared gene expression in iPSC derived275 
neurons with full expansions vs. low repeat controls were compared against the differentially 276 
expressed genes in this study (intermediate repeat vs low repeat).  277 
278 
Generation of stable C9orf72 expressing cell lines, transfection and drug treatments 279 
The generation of an inducible single-copy C9orf72 transgene using Flp-In TRex-HeLa 280 
cells was  as  described previously[31]. All  cell  lines  used  in  this  study  were  maintained  in 281 
DMEM (GE  Healthcare  HyClone,  SH30243.01) with  10%  FBS  (GE  Healthcare  HyClone, 282 
SV30160.03)  and  1%  Pen-Strep  (Thermo  Fisher  Scientific,  15070063)  at  37°C  and  5% 283 
CO2.  Tetracycline (Sigma-Aldrich,  T7660) was  added  (100 ug/ml)  for  18  h  to induce the 284 
expression of C9orf72 transgene. Parental HeLa cells treated with tetracycline were used as 285 
controls in the experiments shown in Figure 6b and 7b. All plasmid transfections in cell lines 286 
were performed using Lipofectamine  2000  (Thermo  Fisher  Scientific,  11668019)  or  287 
TurboFect  (Thermo  Fisher Scientific, R0531) as per the manufacturer’s instruction. For 288 
autophagy experiments, Chloroquine  (CQ, Sigma-Aldrich)  was  dissolved  in  water  (20  mM)  289 
and  used  at 40μM in the media.  Autophagy induction using Earle’s Balanced Salt Solution 290 
(EBSS, Gibco) was incubated on cells following two successive PBS rinses. Incubation time for 291 
each condition is stated in the respective figure legends.  292 
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294 
Results 295 
Screening of CBD patient DNA for C9orf72 expansions 296 
To test the hypothesis that intermediate size expansions in C9orf72 are a risk factor for 297 
CBD, genomic DNA from 354 autopsy confirmed CBD cases was screened using a PCR-based 298 
sizing assay (Figure 1a). We compared CBD patients to controls from a previously published 299 
global meta-analysis of C9orf72 repeat size [73]. We found that 1.84% of alleles from CBD 300 
cases (corresponding to 3.7%, or 13 cases) harbored intermediate length repeat expansions 301 
compared to 0.52% of controls (Figure 1b-c, OR = 3.59, p = 0.00024).  This analysis was based 302 
on a minimum size cutoff of 17 which was determined a priori and based on prior independent 303 
studies[7, 73]. The increase in C9orf72 intermediate repeat allele frequency was not due to an 304 
increase in the frequency of the C9orf72 repeat expansion haplotype between CBD patients 305 
verses non-diseased controls or general global populations (Supplemental Table 3), and we did 306 
not detect any expansions larger than 29 repeats (Supplemental Table 4). We conducted a post-307 
hoc analysis on our CBD cohort for each repeat length cut off below 18 repeats which revealed 308 
that repeats as low as 10 units was associated with CBD (p = 0.026, OR = 1.36), where 61 out of 309 
354 CBD cases had C9orf72 repeat alleles that were at least 10 units.  This included 5 cases 310 
which had two alleles at 10 or greater.  Although this post-hoc analysis is considered 311 
exploratory[9], there appeared to be a somewhat graded increase in CBD risk with increasing 312 
repeat size (Figure 1d, Supplemental Table 5). Overall these results indicate that intermediate 313 
expansions in C9orf72 may be a genetic risk factor for CBD, and the risk may be additive with 314 
higher repeat sizes conferring increased CBD risk. 315 
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316 
C9orf72 expression from intermediate expansion carriers 317 
Next, we determined how intermediate repeat expansions affect expression of the 318 
C9orf72 gene. Previous studies have shown that large expansions in C9orf72, which cause 319 
ALS/FTD, reduces mRNA from the expanded allele[8, 19, 77]. This reduction in expression is 320 
often associated with hypermethylation of the C9orf72 promoter region[41, 52, 61, 81]. To test 321 
whether intermediate expansions alter C9orf72 DNA methylation and mRNA levels, we 322 
analyzed post mortem cerebellum samples from a subset of 47 CBD cases for which frozen 323 
tissue was readily available. We measured repeat expansion size, DNA methylation and C9orf72 324 
mRNA levels of the two major isoforms[76] (Figure 2a, V2 and V3 isoforms). In this subgroup 325 
analysis, we again observed high frequencies of intermediate repeat expansions between 17 and 326 
29 units (Supplemental  Figure 1). Intermediate size expansions did not correlate with 327 
hypermethylation of the promoter region, as is observed in full expansion cases (Supplemental  328 
Figure 2). Surprisingly, total C9orf72 mRNA levels were positively correlated with total C9orf72 329 
repeat size (Figure 2b, R2 = 0.276, p = 0.0034).This positive correlation was not observed for the 330 
major isoform, V2, which has a transcription start site downstream from the repeat expansion 331 
(Figure 2c, R2 = 0.00496, p = 0.717). In contrast, V3 has a transcription start site upstream from 332 
the repeat expansion and shows a robust positive correlation between repeat expansion size and 333 
mRNA levels (Figure 2d, R2 = 0.667, p < 0.0001).  Cases with >17 total repeats exhibited ~2.5 to 334 
5 fold increase in variant 3 mRNA compared to cases with shorter repeats. Finally, analysis of 335 
the variant 3 to variant 2 ratio also reveals a striking positive correlation with larger repeat sizes 336 
(Figure 2e, R2 = 0.849, p < 0.0001). Similar results were obtained when using the largest repeat 337 
allele as opposed to the total C9orf72 repeat length (Figure 2b-d, right). However, total repeat 338 
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number produced a stronger positive correlation to C9orf72 mRNA levels, supporting an 339 
additive effect of repeat size on expression.  340 
To confirm the positive relationship between C9orf72 repeat size and mRNA expression, 341 
we analyzed publicly available SNP eQTL data from the Genotype-Tissue Expression (GTEx) 342 
Project[44]. Large C9orf72 repeat expansion mutations invariably occur within a 140kb 343 
haplotype block with a defined series of SNPs[49, 53].  The SNP rs3849942 is a commonly used 344 
marker for this haplotype block in which the G allele is associated with small non-expanded 345 
C9orf72 alleles, and the A allele is associated with both larger intermediate to full repeat 346 
expansions[19]. We observe the same trend in our CBD genomic DNA cohort where the 347 
rs3849942 A risk allele was associated with larger C9orf72 repeat sizes (Figure 2f). Using 348 
rs3849942 as a marker for longer/intermediate repeats (as full expansions are rare in unselected 349 
populations), we used GTEx data to determine if this SNP is associated with altered C9orf72 350 
expression. We found that the risk allele is significantly associated with increased C9orf72 351 
expression across numerous tissue types, with the largest effect size occurring in neural tissues 352 
(Figure 2g). Expanding our analysis to 20 haplotype defining SNPs[53], we found that 12 of the 353 
SNPs on the risk allele are associated with increased C9orf72 expression in both the cortex and 354 
basal ganglia (Figure 2h ). In contrast, there were no significant eQTL SNPs that led to a 355 
decrease in expression. These results provide additional evidence that intermediate expansions 356 
lead to increased C9orf72 expression. 357 
358 
CRISPR Editing of C9orf72 expansion size in iPSCs 359 
In order to confirm our findings experimentally and to determine whether the risk 360 
haplotype versus the intermediate C9orf72 repeats themselves are driving increased C9orf72 361 
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gene expression, we used CRISPR/cas9 to modify the repeat size in previously characterized 362 
induced pluripotent stem cells (iPSCs) from a non-diseased individual[46]. We used a repair 363 
template containing either 2 or 28 repeats to alter the size of the repeat expansion in iPSCs that 364 
normally have alleles of either 2 or 6 repeats (Figure 3a-b; Supplemental Figure 3). Clonal lines 365 
were derived by FACS and were screened for changes in repeat size and for the presence of the 366 
knocked-in allele by PCR followed by restriction enzyme digest (Figure 3b).  Genotype, 367 
including repeat size, was confirmed by repeat primed PCR (Figure 3c) and Sanger sequencing 368 
(Supplemental Figure 4).  Despite using a repair template with 28 repeats, several different iPSC 369 
clones with repeat sizes ranging from 23 to 28 were obtained.  Additional isogenic iPSC clones 370 
were also obtained with two or six C9orf72 repeats. 371 
Given that both neurons and glial cells are affected in CBD[5], we used the dual SMAD 372 
inhibition method[14, 66] to differentiate edited iPSCs with intermediate C9orf72 expansions 373 
and isogenic controls with small repeats into neural progenitor cells (NPCs) as determined by 374 
uniform expression of the NPC marker Pax6 (Supplemental  Figure 5). RT-qPCR of these edited 375 
NPC lines showed a remarkably consistent pattern of higher C9orf72 mRNA expression in 376 
clones with intermediate C9orf72 repeats compared to isogenic controls with small repeats 377 
(Figure 3d). Consistent with the data from CBD post mortem brain tissue, we again saw no 378 
change in the amount of variant 2 mRNA (Figure 3e) but a robust increase in variant 3 mRNA 379 
levels in all intermediate C9orf72 repeat cell lines (Figure 3f-g). This effect was not an artifact of 380 
neuronal differentiation, as undifferentiated iPSCs also exhibited increased C9orf72 mRNA 381 
levels (Supplemental  Figure 6). Thus, these experiments demonstrate a causal relationship 382 
between intermediate C9orf72 expansions and increased C9orf72 mRNA levels.  383 
384 
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Intermediate repeat carriers do not have RNA foci or DPR pathology 385 
Full expansion carriers have characteristic neuropathology in post mortem brain and 386 
spinal cord tissue that includes nuclear RNA foci of G4C2 transcripts[19] and aggregates of 387 
dipeptide repeat proteins (DPRs) that co-stain with p62[6]. Staining for DPRs using p62 antibody 388 
or DPR specific antibodies (GA, GP and GR) was carried out on 125 CBD cases in hippocampus 389 
and/or cerebellum, including 9 cases with intermediate repeats (repeat sizes 17-29, Figure 4a). 390 
Interestingly, all of these cases were negative for the aggregates typically seen in full expansion 391 
cases (Figure 4a).  Additionally, RNA foci were not detected in CBD cerebellum tissues with 392 
intermediate repeats, nor were they detected in cases with low repeat numbers (Figure 4b). In 393 
comparison, full expansion FTD/ALS cases had abundant DPR aggregates together with RNA 394 
foci in ~18% of nuclei. Thus, the major pathologic hallmarks of full expansion carriers are not 395 
present in CBD cases, leading us to hypothesize that the underlying mechanisms of intermediate 396 
expansions and CBD risk may be distinct from the large repeat expansions that cause ALS/FTD. 397 
398 
Elevated C9orf72 protein and global gene expression changes in intermediate repeat cell 399 
lines 400 
To test whether C9orf72 protein expression is higher in cells with intermediate repeats, 401 
we tested protein expression in isogenic repeat edited NPCs. We observed a consistent ~40% 402 
increase in C9orf72 protein levels in cell lines with intermediate repeats compared to isogenic 403 
low repeat number controls (Figure 5a-b). Thus, intermediate size repeat expansions increase 404 
both C9orf72 mRNA and protein levels.   405 
To determine whether overexpression of C9orf72 in the context of intermediate 406 
repeats alters expression of other genes, we performed RNA sequencing on 3 edited intermediate 407 
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NPC lines and 3 low repeat isogenic control lines (Supplemental table 2, Supplmental file 1). We 408 
found 1,307 genes significantly downregulated (adjusted p-value < 0.05 and fold change > 2) in 409 
intermediate repeat cell lines and 959 genes upregulated (Figure 5c). Next, we performed 410 
overrepresentation analysis on gene ontology pathways in the differentially expressed genes. 411 
Genes that are down regulated in intermediate repeat cell lines (Figure 5d) are highly enriched 412 
for metabolic processes, especially those involving nutrient catabolism. Genes that are 413 
upregulated in intermediate repeat cell lines (Figure 5e) are enriched in vesicle trafficking and 414 
protein degradation pathways including golgi vesicle transport, response to ER stress and 415 
autophagy. We then looked in more detail at specific genes within the most highly dysregulated 416 
biological processes. When categorizing vesicle trafficking genes according to their function[69], 417 
we observe a modest increase in expression of numerous endosomal/lysomal genes, including 418 
C9orf72 (Figure 5f). Interestingly, we observe a consistent and sizable decrease in expression of 419 
genes involved in secretory pathways in intermediate repeat cell lines, indicating a possible 420 
defect in vesicle secretion (Figure 5f). Additionally, key genes involved in autophagy are 421 
modestly increased in intermediates (Figure 5g). However, several genes that have been shown 422 
to regulate autophagy in response to nutrient starvation[3, 71, 85] and ER stress[78] such as 423 
TMEM74 and TMEM74B are markedly downregulated in intermediate repeat cells (Figure 5g), 424 
suggesting a defect in autophagy under stress conditions. Finally, we compared the differentially 425 
expressed genes in our dataset to previously published[24, 63] gene expression studies between 426 
control (low repeat) and full expansion cells derived from ALS/FTD patients. Interestingly, we 427 
see a distinct group of dysregulated genes between control and intermediate repeat cells than 428 
between control and full expansion cells (Figure 5h), indicating that different processes are 429 
affected by intermediate expansions versus full expansions. 430 
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431 
Over-expression of C9orf72 impairs starvation-induced autophagy 432 
Next, we wanted to further validate the changes in biological pathways we observed in 433 
the RNA sequencing data and determine if these were in fact caused by C9orf72 over expression. 434 
Since C9orf72 is known to regulate autophagy[16, 18, 65, 74], we generated an inducible 435 
isogenic HeLa cell line expressing a single-copy of human C9orf72 long isoform without the 436 
repeat expansion tagged with GFP and 6xHis-FLAG tag. We verified that the transgene 437 
expression level is comparable, i.e., 1:1, to that of endogenous C9orf72 and is under the tight 438 
control of tetracycline (Supplmental Figure 7 and [31]). Importantly, the transgene also 439 
associates with the autophagy initiation complex, thereby confirming that the GFP-tagged 440 
C9orf72 recapitulates the known endogenous gene function[31].  As a readout of autophagy, we 441 
utilized an LC3 (microtubule-associated protein light chain 3)-based assay (Figure 6a). During 442 
autophagosome assembly, LC3-I undergoes lipidation via conjugation with a 443 
phosphatidylethanolamine group to become LC3-II [54, 82].  LC3-II is normally rapidly 444 
degraded during autophagy via fusion with the lysosome, but blocking lysosome fusion allows 445 
for accumulation of LC3-II to serve as a marker of autophagic activity[72]. Immunoblotting in 446 
C9orf72 overexpressing cells revealed that basal LC3-II levels are ~20% higher in C9orf72 447 
overexpressing cells compared to parental HeLa cells (lane NGM, normal growth medium, 448 
Figure 6b-c), indicating that either autophagosome production is increased or lysomal 449 
degradation of LC3-II is reduced under normal conditions. When autophagosome-lysosome 450 
fusion was blocked with chloroquine (CQ)[51], LC3-II accumulates at a higher level in CQ-451 
treated condition when compared to their untreated counterparts, and at a similar level between 452 
the parental HeLa and C9orf72 overexpressing cells (Lane NGM+CQ, Figure 6b-c).  453 
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Interestingly, when autophagy was induced using nutrient-deficient medium, EBSS (Earle’s 454 
balance salt solution), the accumulation of LC3-II was reduced by ~40% in the C9orf72 455 
overexpressing cells when compared with parental HeLa cells (Lane EBSS+CQ, Figure 6b-c), 456 
suggesting that C9orf72 overexpression blocks starvation-induced autophagy. To further 457 
corroborate the biochemical findings, a GFP-LC3 stable HeLa cell line[87] was transfected with 458 
C9orf72 construct that was linked via P2A peptide to mCherry to better visualize the transfected 459 
cells. Consistent with our immunoblotting results above, ~50% more LC3-II puncta were 460 
observed at the C9orf72 overexpressing conditions in normal growth media.  (NGM panel, 461 
Figure 6d-e). However, we observed ~30% reduction of LC3-II puncta in C9orf72 462 
overexpressing cells under starvation (EBSS+CQ panel, Figure 6d-e), again indicating that there 463 
is a failure of autophagy initiation in starvation conditions.  To more accurately measure the 464 
actual autophagic flux or rate, a time course without and with chloroquine treatment was 465 
performed (Figure 7a). With the lysosomes blocked, LC3-II accumulated at a similar rate in 466 
C9orf72 overexpressing cells under normal conditions as the parental HeLA cells (Figure 7b-c, 467 
top blot). Under starvation conditions, however, the rate of accumulation was markedly reduced 468 
(Figure 7b-c, bottom blot) compared to the parental HeLa cells. Taken together, these results 469 
suggest that C9orf72 overexpression promotes autophagy under nutrient rich conditions but 470 
limits the cell’s ability to induce autophagy during times of nutrient stress. 471 
472 
Discussion 473 
In this study, we demonstrate that intermediate repeat expansions in C9orf72 may be a 474 
genetic risk factor for CBD, thus broadening the spectrum of neurodegenerative diseases 475 
implicated by this gene. This study highlights the importance of using autopsy confirmed cases 476 
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to better understand the genetics of neurodegenerative diseases that have similar or overlapping 477 
clinical manifestations. Although intermediate repeats are found in only a small percentage of 478 
CBD patients, the magnitude of risk conferred by intermediate repeats is comparable or greater 479 
than other known genetic risk factors for CBD[34]. This study assembled the most CBD cases 480 
yet tested, and due to the rarity of CBD, a replication cohort is not yet available for follow-up 481 
analysis. While we established an a priori hypothesis based on the previously established but 482 
arbitrary cutoff of 17 repeat units or larger to define intermediate expansion carriers, our findings 483 
suggest that both CBD risk and C9orf72 expression increases in an additive manner with 484 
increasing repeat length where perhaps C9orf72 intermediate expansions could be defined as at 485 
least 10 units. Interestingly, initial reports of C9orf72 repeat mutation cohorts, defined at that 486 
time as at least 30 repeats, included one case of autopsy-confirmed CBD[68].  We did not detect 487 
any expansions larger than 29 repeats in our CBD cohort, and intermediate expansion carriers 488 
did not have the characteristic RNA foci and dipeptide repeat pathology seen in full expansions. 489 
Future studies will need to further define the size threshold that determines whether carriers are 490 
more likely to develop risk for CBD versus ALS/FTD. 491 
C9orf72 joins a list of other repeat expansion containing genes in which the length of the 492 
repeat confers a pleiotropic effect on the disease phenotype. For instance, intermediate length 493 
CGG repeats in the gene FMR1 result in the neurodegenerative disease Fragile X-associated 494 
tremor/ataxia syndrome (FXTAS) linked to toxicity of repeat RNA[29], whereas full expansions 495 
lead to near complete silencing of FMR1 and the neurodevelopmental disorder Fragile X 496 
Syndrome[75]. Similarly, intermediate CAG expansions in Ataxin-2 are a risk factor for 497 
ALS[25], whereas full expansions cause spinocerebellar ataxia type 2[62]. For C9orf72, large 498 
expansions cause ALS/FTD[19, 60], whereas we demonstrate that intermediate expansions 499 
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confer ~3.5 fold higher risk for CBD. Full expansions mutations in C9orf72 have been associated 500 
with reduction of C9orf72 gene expression, repeat RNA accumulation, and dipeptide repeat 501 
protein production. [19, 27, 67, 76]  In contrast, we show that intermediate expansions cause an 502 
increase in C9orf72 mRNA levels in both CBD post mortem cerebellum and knock-in isogenic 503 
neural cell lines. This mechanism is also supported by publicly available SNP eQTL data, which 504 
shows that numerous SNPs on the expansion haplotype are associated with increased C9orf72 505 
expression.  Thus, it appears that maintaining proper levels of C9orf72 may be necessary for 506 
proper  neuronal function, with increased expression observed in CBD patients and decreased 507 
expression observed in ALS/FTD patients. 508 
C9orf72 is thought to function as Rab guanine exchange factor[38], which participates in 509 
a host of vesicle trafficking pathways[55]. C9orf72 has been shown to regulate endocytosis[26], 510 
vesicle secretion[4], intracellular trafficking[4, 26, 58, 67] and autophagy[16–18, 74, 79, 83]. 511 
Indeed, we observe numerous gene expression changes in all of these vesicle trafficking 512 
pathways in knock-in NPCs with intermediate expansions. The large number of significant gene 513 
expression changes detected in this study is likely due to the depth of sequencing (~100 million 514 
reads/sample) and the use of isogenic CRISPR edited controls, which removes variability due to 515 
genetic background. Particularly striking changes were observed in genes involved in vesicle 516 
secretion and autophagy. The involvement of autophagy pathways in numerous 517 
neurodegenerative diseases has been well documented [55], and increased levels of C9orf72 may 518 
enhance CBD risk by disrupting autophagy pathways necessary for responding to stress. C9orf72 519 
has been shown to regulate autophagy initiation through the ULK1 complex[31, 65, 79], and we 520 
observe increased expression of autophagy initiation genes in our intermediate repeat knockin 521 
NPCs.  Interestingly, over expression of C9orf72 seems to increase autophagy initiation under 522 
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normal conditions, but inhibits autophagy induction under nutrient stress. Several other studies 523 
have implicated C9orf72 as regulator of the cellular stress response[2, 16, 43, 47], and we 524 
observe dysregulation of genes involved in the ER stress response and nutrient biosynthesis 525 
pathways in intermediate repeat knockin NPCs. In particular, we found the gene TMEM74 and 526 
its paralog TMEM74B to be high downregulated in C9orf72 intermediate repeat knockin NPCs. 527 
TMEM74 has been shown to be a potent activator of autophagy induced via nutrient 528 
starvation[85] and is thought to function via a unique pathway that does not require initiation via 529 
the canonical ULK1 autophagy initiation complex[71].  This alternative initiation pathway may 530 
be affected by increased C9orf72 levels and could explain why we observe an autophagy defect 531 
in C9orf72 over expressing cells under nutrient starvation. Future studies will need to further 532 
define the molecular mechanisms by which C9orf72 overexpression alters specific autophagy 533 
pathways. 534 
Overall, our results illustrate the complexity of C9orf72 repeat expansion mutations, with 535 
the length of expansion conferring risk for different neurodegenerative diseases via opposing 536 
mechanisms. Notably, the proportion of CBD cases with intermediate C9orf72 repeats is still 537 
relatively low (~4%) indicating that the overall genetic risk associated with intermediate repeats 538 
is modest.  Likewise, given that CBD is a rare disease, an otherwise normal individual harboring 539 
an intermediate repeat is unlikely to develop CBD.   Finally, our findings indicate that autophagy 540 
pathways are dysregulated by elevated C9orf72 levels and suggest a link between C9orf72 541 
expression and neurodegenerative disease.  542 
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547 
Figure 1: C9orf72 repeat sizing of CBD. a) Example capillary electrophoresis traces of CBD 548 
cases measured from genomic DNA using a fluorescent PCR assay with genotypes of 2,2 (top), 549 
2,18 (middle) or 9,20 (bottom). b) Summary statistics for repeat size screening of CBD cases (n 550 
= 708 alleles) and previously published controls (n = 11,774 alleles)[73].  Fisher’s exact test: OR 551 
= 3.59, 95% CI = 1.80 – 6.65, p = 0.000238. c) Allele frequencies of repeat sizes in CBD cases 552 
and controls. The number of alleles in the CBD cohort for each size is depicted above the bars. 553 
d) Results of Fisher’s exact test between CBD cases and controls at each allele size cutoff.554 
Dotted gray line represents p < 0.05 significance level.  555 
556 
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560 
Figure 2: Effect of intermediate repeats on C9orf72 expression. a) Diagram of the C9orf72 561 
locus with mRNA and protein isoforms. Transcription start sites (TSS) are labeled for each 562 
mRNA variant on the genomic DNA. Colored arrows on the mRNA depict primers used for RT-563 
qPCR. b) Correlation between total C9orf72 repeat size (left) or largest allele (right) and 564 
C9orf72 mRNA levels from all variants measured by RT-qPCR using RNA from CBD patient 565 
cerebellum (Total repeats: n = 29, R2 = 0.276, p = 0.0034; Largest allele: n = 29, R2 = 0.1613, p 566 
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= 0.0308). Data is normalized to samples with 4 total repeats.  c) Correlation between total 567 
C9orf72 repeat size (left) or largest allele (right) and variant 2 mRNA levels (Total repeats: n = 568 
29, R2 = 0.00496, p = 0.717; Largest allele: n = 29, R2 = 0.04432, p = 0.2730). d) Correlation 569 
between total C9orf72 repeat size (left) or largest allele (right) and variant 3 mRNA levels (Total 570 
repeats: n = 29, R2 = 0.667, p < 0.0001; Largest allele: n = 29, R2 = 0.4874, p < 0.0001). e) 571 
Correlation between total C9orf72 repeat size (left) or largest allele (right) and the variant 3 572 
mRNA to variant 2 mRNA ratio (Total repeats: n = 29, R2 = 0.849, p < 0.0001; Largest allele: n 573 
= 29, R2 = 0.8869, p < 0.0001). f) Genotyping results for rs3849942 in the CBD patient genomic 574 
DNA cohort (n = 710 alleles). The A allele is associated with intermediate and full length repeat 575 
expansions. g) SNP eQTL data from the Gtex project showing the effect of rs3849942 on 576 
C9orf72 expression in basal ganglia (left, p = 9.00E-07) and tibial nerve (right, p = 2.80E-16). 577 
For box plots, center line indicates median, boxes are upper and lower quartiles, error bars are 578 
standard error of the mean. Numbers of samples are indicated below each group. h) Normalized 579 
GTEx eQTL effect size from cortex and basal ganglia on C9orf72 expression for all 20 SNPs in 580 
the consensus repeat expansion risk haplotype (from Mok et al. 2012[53]). * indicates SNPs with 581 
a significant effect on C9orf72 expression.  582 
583 
27 
584 
Figure 3: CRISPR/cas9 knock-in of intermediate repeats into iPSCs. a) Diagram of C9orf72 585 
genomic locus and double stranded repair templates used for knocking in intermediate repeats. 586 
Black triangle represents the CRISPR/cas9 cut site. Black arrows indicate the PCR primers used 587 
in (b). Red boxes indicate the G4C2 repeat. Blue boxes indicate the 2 bp substitution included in 588 
the repair templates to mutate the Cas9 PAM site and generate a PvuII restriction enzyme site. b) 589 
PCR (top) and PvuII digest (bottom) of CRISPR edited iPS cell lines using PCR primers 590 
spanning the CRISPR cas9 cut site and repeat expansion. Digestion of the PCR product indicates 591 
that HDR occurred. c) Capillary electrophoresis traces of repeat primed PCR from CRISPR 592 
edited iPSCs. d-g) RT-qPCR from the indicated variants of C9orf72 from neural progenitor cells 593 
differentiated from CRISPR edited iPSCs. Light bars correspond to low repeat lines while black 594 
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bars correspond to intermediate repeat lines. N = 3 biological replicates per cell line; ANOVA 595 
(All variants: F = 18.3, p = 0.0001; Variant 2: F= 2.9, p = 0.08; Variant 3: F = 216.0, p < 0.0001; 596 
V2/V3: F = 460.0, p < 0.0001) followed by Bonferroni post hoc test between low and 597 
intermediate repeat cell lines. **p < 0.01, ***p < 0.001, ****p < 0.0001. Error bars are standard 598 
error of the mean. 599 
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Figure 4: Absence of repeat pathology in intermediate expansion cases. a) Representative 634 
Immunohistochemistry images of non-expanded control (n=4 cases) or non-expanded CBD (n = 635 
116 cases), intermediate expansion CBD (n = 9 cases), and full expansion FTD/ALS (n = 5 636 
cases) post mortem cerebellar samples using an anti-GA antibody. Intermediate expansion 637 
carriers were also negative for p62 or GP/GR aggregates. Scale bar 10μm. b) Representative 638 
fluorescence in situ hybridization images of non-expanded control (n=4 cases) or non-expanded 639 
CBD (n = 12 cases), intermediate expansion CBD (n = 5 cases), and full expansion FTD/ALS (n 640 
= 5 cases) post mortem cerebellar samples using a probe complimentary to the G4C2 repeat.  641 
Scale bar 5μm. 642 
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Figure 5: Elevated C9orf72 protein levels and gene expression changes in intermediate 648 
repeat NPCs 649 
a) Western blot of protein expression from CRISPR edited NPCs. N = 2 low repeat and 3650 
intermediate repeat number cell lines. Representative blot of 2 technical replicates is shown. b) 651 
Quantification of C9orf72 protein levels from repeat edited NPCs. Protein expression was 652 
normalized to GAPDH as a loading control and the average of 2 technical replicates is reported. 653 
N = 2 low repeat and 3 intermediate repeat number cell lines. Two tailed t-test, p = 0.0145. Error 654 
bars are standard error of the mean. c) RNA sequencing analysis of 3 low repeat NPC lines (max 655 
repeat size 2 or 6) and 3 intermediate repeat (max repeat size 23, 27 or 28) NPC lines. 656 
Differentially expressed genes with an adjusted p-value < 0.05 and greater than 2 fold change are 657 
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depicted as red dots. d-e) Overrepresentation analysis of biological processes on differentially 658 
downregulated genes (d) or upregulated genes (e) in NPCs with intermediate repeats. Labels 659 
highlight the top 10 most significant biological processes. f) Changes in gene expression of 660 
genes involved in vesicular trafficking. All genes shown are significantly differentially expressed 661 
(adjusted p < 0.05) between low repeat and intermediate repeat NPCs. g) Changes in gene 662 
expression of genes involved in autophagy. All genes shown are significantly differentially 663 
expressed (adjusted p < 0.05) between low repeat and intermediate repeat NPCs. h) Comparison 664 
of overlap in differentially expressed genes between low repeat NPCs versus intermediate repeat 665 
NPCs (this study) or low repeat vs full expansion neurons from patient derived iPSCs from two 666 
previous studies [24, 63]. Only genes with adjusted p < 0.05 and fold change > 2 were used in 667 
this comparison.  668 
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Figure 6: Autophagy defects in inducible C9orf72 over-expressing cells 671 
a) Schematic of experimental procedure for LC3-II protein detection in C9orf72 HeLa stable672 
cells. b)  Representative western blot showing LC3-II expression levels of parental HeLa cells 673 
and C9orf72 cells first treated with treated with tetracycline to induce C9orf72 transgene 674 
expression then with EBSS and/or CQ for 1 hour. c)  Bar  chart  corresponding  to  (a)  showing  675 
pooled  data  of  LC3-II  protein  levels expressed  as  fold  change  over  parental  HeLa  cells in 676 
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normal growth media without CQ treatment.  Data represents three independent experiments 677 
with * p<0.05, Student’s t-test.  d)  Schematic  of  experimental procedure  for  the  detection  of  678 
LC3-II  puncta  using  fluorescence  microscopy  in  parental HeLa  cells overexpressing  GFP-679 
LC3  and  mCherry  (control)  or  C9orf72-P2A-mCherry  plasmids.  The cells were treated with 680 
NGM. EBSS, EBSS+CQ or NGM+CQ for 2 hours and green puncta associated with GFP-LC3 681 
in mCherry-overexpressing cells were analyzed using ImageJ particle count. At least 25 cells 682 
were analyzed per treatment group. Scale bar = 20 µm. e) Bar chart corresponds to the average 683 
LC3 puncta count in (d) with * p < 0.05, Student’s t-test. Error bars represent standard error of 684 
the mean (S.E.M). 685 
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Figure 7. Kinetics of starvation induced autophagy in C9orf72 over-expressing cells 694 
a) Schematic of time-course experiments on autophagy in C9ORF72 HeLa stable cells. b)695 
Representative western blot showing LC3-II expression levels of parental HeLa cells and 696 
C9orf72 cells treated with CQ under either normal growth media (NGM) or EBSS conditions for 697 
0, 1, 2, and 3 hours. c) Time course chart corresponding to (b) showing pooled data of LC3-II 698 
protein levels expressed as fold change over respective controls, i.e. parental HeLa cells or 699 
C9orf72 cells grown in normal growth media without CQ treatment. Data represents three 700 
independent experiments with error bars representing standard error of the mean (S.E.M). 701 
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Supplemental Information for 
C9orf72	Intermediate	Repeats	Confer	Risk	for	Corticobasal	Degeneration	via	
increased	C9orf72	Expression	and	disruption	of	autophagy	
Supplemental Figure 1: Repeat Expansion sizes in CBD post mortem cerebellum cohort. 
Repeat sizes from CBD post mortem cerebellum detected using fluorescent PCR followed by 
capillary electrophoresis. N = 47 cases. 
Supplemental Figure 2: DNA methylation analysis at the C9orf72 promoter of CBD post 
mortem cerebellum cohort and comparison to full expansion cases. DNA methylation was 
measured using HhaI digest followed by qPCR on CBD cases (n = 47) and full expansion 
ALS/FTD cases (n= 20). Within the CBD case group, there is no significant association between 
repeat size and DNA methylation of C9orf72 (R2 = 0.01012, p = 0.5010).  
C9orf72 Homologous Repair template (5’ to 3’) 
CCGCTAGGAAAGAGAGGTGCGTCAAACAGCGACAAGTTCCGCCCACGTAAAAGATGACGCTTGGTGTGTCAGCCGTC
CCTGCTGCCCGGTTGCTTCTCTTTTGGGGGCGGGGTCTAGCAAGAGCAGGTGTGGGTTTAGGAGGTGTGTGTTTTTG
TTTTTCCCACCCTCTCTCCCCACTACTTGCTCTCACAGTACTCGCTGAGGGTGAACAAGAAAAGACCTGATAAAGAT
TAACCAGAAGAAAACAAGGAGGGAAACAACCGCAGCCTGTAGCAAGCTCTGGAACTCAGCTGTCGCGCGCTAGGGG
CCGGGGCCGGGGCGTGGTCGGGGCGGGCCCGGGGGCGGGCCCGGGGCGGGGCTGCGGTTGCGGTGCCTGCGCCC
GCGGCGGCGGAGGCGCAGGCGGTGGCGAGTGGGTGAGTGAGGAGGCGGCATCCTGGCGGGTGGCTGTTTGGGGTTCG
GCTGCCGGGAAGAGGCGCGGGTAGAAGCGGGGGCTCTCCTC 
 
Supplemental Figure 3: Homologous template and gRNA sequence used to edit the endogenous 
C9orf72 repeat expansion size. Homologous template containing either 2 or 28 G4C2 repeat units 
was cloned via PCR and inserted into P-gem Easy T vector. The 20bp CRISPR gRNA sequence 
is underlined and the 2 bp mutation which destroys the PAM site and introduces a PvuII 
restriction enzyme site is highlighted in red. The G4C2 expansion site is in bold (shown here is 2 
repeat units).  
 
 
 
 
 
 
 
 
 
 
 
 
Supplemental Figure 4: Sanger sequencing of repeat edited iPSCs. Representative 
chromatograms of CRISPR edited iPSCs that were PCR cloned and Sanger sequenced. All 
CRIPSR edited cell lines included in this study were matched to have the same 8 bp deletion on 
the non-repeat edited allele, likely due to non-homologous end joining. 
Supplemental Figure 5:  Characterization of iPSC derived neural progenitor cells. 
Immunofluorescence images of day 12 post neural induction CRISPR edited NPCs stained with 
either pax6 (NPC marker) or Oct4 (iPSC marker).  The number separated by a comma indicates 
repeat sizes of each allele in the NPC cell lines. 
Supplemental Figure 6:  C9orf72 variant 3 mRNA levels from undifferentiated, repeat edited 
iPSCs. 1 way ANOVA followed by Bonferroni multiple comparison test. ****p < 0.0001. All 
intermediate repeat cell lines are significantly different than both low repeat controls 
Supplemental Figure 7: Expression of C9orf72 transgene is comparable to the endogenous 
C9orf72 and is induced by tetracycline. a) Immunoblots of parental HeLa cells and the inducible 
isogenic C9orf72 cells used in this study. Both groups were treated with tetracycline for 18 
hours. A polyclonal antibody (Santa Cruz Biotechnology, sc-138763) was used to detect the 
endogenous C9orf72 (black arrowhead) and the C9orf72 transgene (green arrowhead). The level 
of transgene is comparable to endogenous C9orf72 and the levels of endogenous C9orf72 are 
similar between parental HeLA cells and C9orf72 inducible cells. b) Immunoblots of C9orf72 
transgene with or without tetracycline induction. Inducible isogenic C9orf72 cells were cultured 
without (-) or with (+) tetracycline and subjected to GFP-immunoprecipitation to enrich for 
C9orf72 transgene. Input and GFP-immunoprecipitants were probed with FLAG antibody to 
detect C9orf72 transgene. C9orf72 transgene can only be detected after tetracycline treatment.  
Table S1: Primers and CRISPR gRNAs 
Forward Primer Sequence   Reverse Primer Sequence  Assay  Figure 
6FAM-CAAGGAGGGAAACAACCGCAGCC GCAGGCACCGCAACCGCAG Sizing of C9orf72 Repeats  1a‐c 
6FAM-AGTCGCTAGAGGCGAAAGC TACGCATCCCAGTTTGAGACG  Repeat Expansion Detection  1a‐c; 3c 
TACGCATCCCAGTTTGAGACGGGGGCCGGGGCCGGGGCCGGGG Repeat Expansion Detection  1a‐c; 3c 
CCCACTTCATAGAGTGTGTGTTG  TTCCATTCTCTCTGTGCCTTC  Total C9orf72 mRNA (all variants)  2b, 3d 
CGGTGGCGAGTGGATATCTC  TGGGCAAAGAGTCGACATCA  C9orf72 variant 2 mRNA  2c, 3e 
GCAAGAGCAGGTGTGGGTTT  TGGGCAAAGAGTCGACATCA  C9orf72 variant 3 mRNA  2d, 3f 
GAGGAGAGCCCCCGCTTCTAC  CCGCTAGGAAAGAGAGGTGCG  HDR analysis of repeat edited iPSCs  3b, S3 
CACCGTGTAGCAAGCTCTGGAACTC  aaacGAGTTCCAGAGCTTGCTACAC    CRISPR gRNA sequences for repeat editing  3a‐c 
CAGTGTGAAAATCATGCTTGAGAGA  TTTGTGCTTGGTAGGCAGTG  DNA methylation analysis  S2 
Table S2: RNA sequencing of intermediate repeat NPCs raw read counts 
Sample  Repeat Size  Total Reads 
Short Repeat 1 2,6 109337673 
Short Repeat 2 2,2 108537553 
Short Repeat 3 2,6 118024548 
Intermediate Repeat 1 2,23 125527873 
Intermediate Repeat 2 6,28 121998215 
Intermediate Repeat 3 27,27 131039648 
Table S3: Evaluation of C9orf72 Risk haplotype marker rs3849942 A in CBD cases vs 
control populations 
Cohort rs3849942 A Risk Allele Frequency Chi Square Test  Odds Ratio (95% CI) 
CBD cases 159 / 698 (22.78%) 
Controls from Beck et al. 2013 2,597 / 10,400 (24.97%) X2 = 1.568, p = 0.2105 (n.s.) 0.8863 (0.7385-1.064) 
Gobal populations (dbSNP) 35,048/162,186 (21.6%) X2 = 0.4124, p = 0.5207 (n.s.) 1.064 (0.8913-1.271) 
Table S4: Repeat sizes of CBD cases with intermediate expansions  
Case Number  Repeat Size Allele 1  Repeat Size Allele 2 
1  2  29 
2  2  26 
3  2  22 
4  2  22 
5  6  21 
6  6  21 
7  9  20 
8  2  18 
9  5  17 
10  2  17 
11  14  17 
12  2  17 
13  2  17 
Table S5: Comparison of CBD cohort vs Theuns. et al 2014 controls at each allele cutoff 
Repeat Size Cutoff  P‐Value (Fisher Exact Test)  Odds Ratio 
3 0.876300 0.9853727 
4 0.640200 0.9612321 
5 0.638300 0.9609401 
6 0.700700 0.9653403 
7 0.963300 1.006105 
8 0.499400 1.064384 
9 0.209900 1.182729 
10 0.026040* 1.359480 
11 0.108800 1.292946 
12 0.032910* 1.498095 
13 0.073220 1.489279 
14 0.128100 1.491891 
15 0.061270 1.757263 
16 0.004179** 2.512414 
17 0.0002376**** 3.591016 
